×
Hero Background
English
Chinese
French
Japanese
Korean
German
Spanish

Europe Gastrointestinal Drugs Market Size

ID: MRFR/Pharma/0165-HCR
85 Pages
Kinjoll Dey
October 2025

Europe, Middle East and Africa Gastrointestinal Drugs Market Research Report, by Drug Category (Acid Neutralizers, Laxatives and Antidiarrheal, Anti-inflammatory drugs), By Route of Administration (Oral, Parenteral, Rectal), By Disease Type (Gastroesophageal Reflux Disease, Inflammatory Bowel Disease), by end user (Hospital Pharmacies, Retail Pharmacies) - Forecast till 2035

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Europe Gastrointestinal Drugs Market Infographic
Purchase Options

Europe Gastrointestinal Drugs Size

Europe Gastrointestinal Drugs Market Growth Projections and Opportunities

Disease Prevalence and Demographics: The prevalence of gastrointestinal diseases in Europe, the Middle East, and Africa has a major impact on the market for GI medications in these regions. The need for efficient GI drugs is influenced by a number of factors, including changing food preferences, lifestyle modifications, and aging populations. Healthcare Infrastructure: The market for GI medications is heavily influenced by the caliber and accessibility of the healthcare infrastructure. Better diagnosis and treatment of gastrointestinal problems can be achieved in developed European countries thanks to their strong healthcare systems. Still, in other regions of Africa and the Middle East, inadequate healthcare infrastructure may hinder market expansion. Regulatory Environment: Strict regulatory frameworks apply to the pharmaceutical industry, which includes GI medicines. The observance of laws established by health authorities in Europe, the Middle East, and Africa has an impact on pharmaceutical firms' market entrance tactics, approval procedures, and medication development. Economic Factors: The market for gastrointestinal pharmaceuticals is influenced by a number of economic factors, such as GDP growth, healthcare spending, and medication affordability in the area. Economic downturns may impact market dynamics on patients' access to and affordability of pharmaceuticals. Patient Education and Awareness: One important consideration is the general public's degree of knowledge and awareness regarding gastrointestinal health. The need for GI medications is fueled by patient education programs, awareness campaigns, and the work of medical professionals in promoting early diagnosis and treatment. Technological Developments in Medicine: The diagnosis and management of gastrointestinal problems are impacted by developments in medical technology, including imaging methods and diagnostic instruments. Personalized medicine, medication delivery methods, and formulation innovations all support market expansion and competitiveness. Cultural and food Influences: The incidence of gastrointestinal illnesses is influenced by a variety of cultural customs and food habits across Europe, the Middle East, and Africa. Pharmaceutical firms must take into account cultural issues that impact treatment adherence and modify medications to fit local food habits.

Europe Gastrointestinal Drugs Market Size Graph
Author
Kinjoll Dey
Research Analyst Level I

He is an extremely curious individual currently working in Healthcare and Medical Devices Domain. Kinjoll is comfortably versed in data centric research backed by healthcare educational background. He leverages extensive data mining and analytics tools such as Primary and Secondary Research, Statistical Analysis, Machine Learning, Data Modelling. His key role also involves Technical Sales Support, Client Interaction and Project management within the Healthcare team. Lastly, he showcases extensive affinity towards learning new skills and remain fascinated in implementing them.

Leave a Comment

Market Summary

The Europe, Middle East and Africa Gastrointestinal Drugs market is projected to grow significantly over the next decade.

Key Market Trends & Highlights

Europe, Middle East and Africa Gastrointestinal Drugs Key Trends and Highlights

  • The market valuation is expected to increase from 11.8 USD Billion in 2024 to 23.8 USD Billion by 2035.
  • A compound annual growth rate (CAGR) of 6.58 percent is anticipated from 2025 to 2035.
  • The growth trajectory suggests a robust demand for gastrointestinal drugs across the region.
  • Growing adoption of advanced therapeutic options due to increasing prevalence of gastrointestinal disorders is a major market driver.

Market Size & Forecast

2024 Market Size 11.8 (USD Billion)
2035 Market Size 23.8 (USD Billion)
CAGR (2025-2035) 6.58%
Largest Regional Market Share in 2024 latin_america)

Major Players

AstraZeneca Plc., Johnson & Johnson, Takeda Pharmaceutical Company Limited, Eisai Co., Ltd., Valeant Pharmaceuticals Inc., Sanofi Ltd., Abbott Laboratories, Allergan Plc, Bayer AG, Janssen Biotech Inc., AbbVie Inc., GlaxoSmithKline Plc., Boehringer Ingelheim GmbH

Market Trends

Europe Gastrointestinal Drugs Market Market Drivers

Market Segment Insights

Regional Insights

Key Companies in the Europe Gastrointestinal Drugs Market market include

Industry Developments

Market Segmentation

Report Scope

Attribute/Metric Details
  Market Size 2032  USD 20.01 Billion
  CAGR   6.0% (2024-2032)
  Base Year   2023
  Forecast Period   2024-2032
  Historical Data   2020
  Forecast Units   Value (USD Billion)
  Report Coverage Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered Drug Category, Route of Administration, Disease Type  and End-user
  Geographies Covered North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors AstraZeneca Plc.(UK), Johnson & Johnson (US), Takeda Pharmaceutical Company Limited (Japan), Eisai Co., Ltd. (Japan), Valeant Pharmaceuticals Inc. (US), Sanofi Ltd. (France), Valeant (US), Abbott Laboratories(US), Allergan Plc (US), Bayer AG (Germany), Janssen Biotech Inc. (US), AbbVie Inc. (US), Janssen Biotech (US), GlaxoSmithKline Plc. (UK), Boehringer Ingelheim GmbH (Germany)
  Key Market Opportunities Increasing awareness about the availability of treatment
  Key Market Drivers Increasing prevalence of many gastrointestinal disease

FAQs

  1. INTRODUCTION
    1. DEFINITION
      1. RESEARCH OBJECTIVE
      2. ASSUMPTIONS & LIMITATIONS
    2. SCOPE OF STUDY
    3. LIMITATIONS
    4. MARKET STRUCTURE:
  2. RESEARCH METHODOLOGY
    1. RESEARCH PROCESS:
    2. PRIMARY RESEARCH
    3. SECONDARY RESEARCH:
  3. MARKET DYNAMICS
    1. DRIVERS
    2. RESTRAINTS
    3. OPPORTUNITIES
    4. MACROECONOMIC INDICATORS
  4. MARKET FACTOR ANALYSIS
    1. PORTERS
    2. FIVE FORCES MODEL
    3. BARGAINING POWER
    4. OF SUPPLIERS
    5. BARGAINING POWER OF BUYERS
    6. THREAT OF NEW ENTRANTS
    7. THREAT OF SUBSTITUTES
    8. INTENSITY
    9. OF RIVALRY
  5. EUROPE, MIDDLE EAST
  6. AND AFRICA GASTROINTESTINAL DRUGS MARKET, BY DRUG CATEGORY
    1. ACID NEUTRALIZERS
    2. H2 ANTAGONISTS
    3. DRUGS
  7. ANTACIDS
  8. PROTON PUMP INHIBITORS
  9. OTHERS
    1. LAXATIVES AND ANTIDIARRHEAL
    2. ANTIEMETIC
    3. ANTI-INFLAMMATORY
    4. OTHER
  10. EUROPE,
  11. MIDDLE EAST AND AFRICA GASTROINTESTINAL DRUGS MARKET, BY ROUTE OF ADMINISTRATION
    1. ORAL
    2. PARENTERAL
    3. RECTAL
  12. EUROPE, MIDDLE EAST AND AFRICA
    1. GASTROINTESTINAL DRUGS MARKET, DISEASE TYPE
    2. GASTROESOPHAGEAL
    3. REFLUX DISEASE
    4. INFLAMMATORY BOWEL DISEASE
    5. OTHER
  13. EUROPE, MIDDLE EAST AND AFRICA GASTROINTESTINAL
  14. DRUGS MARKET
    1. HOSPITAL PHARMACIES
    2. RETAIL PHARMACIES
    3. OTHER
  15. EUROPE, MIDDLE EAST AND AFRICA GASTROINTESTINAL DRUGS MARKET, BY REGION
    1. INTRODUCTION
    2. EUROPE
      1. WESTERN EUROPE
    3. GERMANY
    4. SPAIN
    5. REST OF WESTERN EUROPE
    6. EASTERN EUROPE
    7. MIDDLE EAST &
    8. AFRICA
  16. COMPETITIVE LANDSCAPE
    1. MAJOR STRATEGIES ADOPTED BY MARKET PLAYERS
      1. STRATEGIC PARTNERSHIP
      2. MERGER & ACQUISITION
    2. COMPANY PROFILE
    3. ABBVIE
      1. OVERVIEW
      2. FINANCIALS
      3. KEY DEVELOPMENTS
      4. OVERVIEW
      5. FINANCIALS
      6. KEY DEVELOPMENTS
      7. OVERVIEW
      8. FINANCIALS
      9. STRATEGY
      10. KEY
    4. INC.
    5. PRODUCT OVERVIEW
    6. ASTRAZENECA
    7. PRODUCT OVERVIEW
    8. JOHNSON & JOHNSON
    9. PRODUCT OVERVIEW
    10. DEVELOPMENT
    11. TAKEDA PHARMACEUTICAL
      1. OVERVIEW
      2. PRODUCT
      3. FINANCIALS
      4. KEY
    12. COMPANY LIMITED
    13. OVERVIEW
    14. DEVELOPMENTS
    15. ALLERGAN PLC
      1. PRODUCT OVERVIEW
      2. FINANCIALS
    16. OVERVIEW
    17. KEY DEVELOPMENTS
    18. OTHERS

Europe, Middle East and Africa Gastrointestinal Drugs Market Segmentation

Market Segmentation Overview

  • Detailed segmentation data will be available in the full report
  • Comprehensive analysis by multiple parameters
  • Regional and country-level breakdowns
  • Market size forecasts by segment
Infographic

Free Sample Request

Kindly complete the form below to receive a free sample of this Report

Get Free Sample

Customer Strories

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Victoria Milne

Founder

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization
Direct Access to Analyst
Deliverable Format
Platform Access
Discount on Next Purchase 10% 15% 15%
Printable Versions